NeuroBytes: Discontinuation of Multiple Sclerosis Disease Modifying Therapies in Later Life
Course Description
Learning Objectives
- Better inform their Multiple Sclerosis patients of the risks and benefits of discontinuing disease modifying therapies later in life.
Date of Release
Confidentiality of Data
Faculty & Disclosures
PGY-4 Neurology Resident
New York Presbyterian - Wiell Cornell
New York, NY
*Dr. Langan has nothing to disclose.
Editor
REBECCA G. STRAUS FRABER, MD
Associate Professor of Neurology
Columbia University Medical School
New York, NY
Dr. Straus Farber has received personal compensation in the range of $0-$499 for serving as a Consultant for Genentech. Dr. Straus Farber has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for FKB Law. The institution of Dr. Straus Farber has received research support from Biogen. The institution of Dr. Straus Farber has received research support from Novartis.
Reviewer
ADAM QUICK, MD
Associate Professor of Neurology
The Ohio State university Wexner Medical Center
Columbus, OH
*Dr. Quick has nothing to disclose.
Voiceover Artist
BENJAMIN STODDART
Senior Trainee Education Administrator
American Academy of Neurology
Minneapolis, MN
Mr. Stoddart has nothing to disclose
NeuroBytes Staff
Xiaoyu Sun, Associate Director, eLearning
Minneapolis, MN
*Ms. Sun has nothing to disclose.
Robert Rook, Manager, eLearning
Minneapolis, MN
*Mr. Rook has nothing to disclose.